Treatment of Hemophilia A Patients With FVIII Inhibitors
Condition: Hemophilia A Interventions: Biological: Nuwiq; Biological: Octanate; Biological: Wilate; Biological: Emicizumab; Biological: Recombinant factor VIIa (rFVIIa); Biological: Activated prothrombin complex concentrate (aPCC) Sponsors: Emory University; Octapharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials